| Ages | |||
---|---|---|---|---|
Gene | 3 wks | 5 wks | 7 wks | 16 wks |
Cell cycle: cyclins | Â | Â | ||
CCNA1 | n.s | n.s | n.s | +4.4x in rcd1 |
+2.2x in xlpra2 | ||||
+3.0x in erd (11.9–14.1 w) | ||||
CCNA2 | n.s | n.s | +2.0x in rcd1 | n.s |
+2.2x in xlpra2 | ||||
+2.2x in erd (6.4 w) | ||||
+3.2x in erd (8.3–9.9 w) | ||||
CCNB1 | n.s | n.s | n.s | +3.3x in rcd1 |
+2.8x in xlpra2 | ||||
CCND1 | n.s | n.s | n.s | +2.4x in rcd1 |
+2.7x in xlpra2 | ||||
CCND3 | n.s | n.s | n.s | +2.8x in rcd1 |
CCNE1 | n.s | +2.4x in rcd1 | +2.7x in rcd1 | +5.5x in rcd1 |
+4.1x in xlpra2 | +5.1x in xlpra2 | |||
+2.8x in erd (6.4 w) | +10x in erd (11.9–14.1 w) | |||
+5.7x in erd (8.3–9.9 w) | ||||
Cell cycle: cyclin-dependent kinases | Â | Â | ||
CDK1 | n.s | −2.1x in rcd1 | −13.3x in rcd1 | −2.2x in rcd1 |
−10.2x in xlpra2 | −3.4x in xlpra2 | |||
−8.4x in erd (6.4 w) | −6.0x in erd (11.9–14.1 w) | |||
−6.9x in erd (8.3–9.9 w) | ||||
CDK2 | +2.7x in rcd1 | n.s | n.s | +3.4x in rcd1 |
CDK4 | +2.2x in rcd1 | n.s | n.s | +2.4x in rcd1 |
CDK6 | +3.6x in rcd1 | n.s | n.s | +2.9x in rcd1 |
+2.5x in xlpra2 | +2.1x in xlpra2 | |||
Cell division cycle phosphatases | Â | Â | ||
CDC25A | n.s | n.s | n.s | n.s |
CDC25B | n.s | n.s | n.s | n.s |
CDC25C | n.s | n.s | n.s | +2.1x in rcd1 |
+2.7x in xlpra2 | ||||
Cyclin-dependent kinase inhibitors | Â | Â | ||
CDKN1A | n.s | n.s | n.s | n.s |
CDKN1B | n.s | n.s | n.s | n.s |
CDKN2A | −3.8x in rcd1 | n.s | +3.0x in erd (8.3–9.9 w) | n.s |
Cell cycle transcription regulators | Â | Â | ||
BMI1 | n.s | n.s | n.s | n.s |
E2F1 | +2.0x in rcd1 | n.s | n.s | +6.2x in rcd1 |
+2.6x in xlpra2 | ||||
+3.7x in xlpra2 | ||||
RB1 | +2.1x in rcd1 | n.s | n.s | n.s |
+5.5x in xlpra2 | ||||
Hippo signaling/NDR kinases | Â | Â | ||
LATS1 | n.s | n.s | n.s | +2.6x in erd (11.9–14.1 w) |
LATS2 | n.s | n.s | n.s | n.s |
MOB1A | n.s | n.s | n.s | +2.5x in erd (11.9–14.1 w) |
NDR1 | n.s | n.s | n.s | +2.1x in erd (11.9–14.1 w) |
STK38L (NDR2) (exons 4–5) | n.s | n.s | No expression in erd | No expression in erd |
STK38L (NDR2) (exons 6–7) | n.s | n.s | n.s | n.s |
Eye development regulation via proliferation/apoptosis | Â | |||
PAX6 | n.s | n.s | −2.5x in erd (6.4 w) | +2.2x in rcd1 |
PCNA | n.s | n.s | n.s | n.s |
PR function | Â | Â | Â | |
GRK1 | n.s | −2.0x in rcd1 | −3.9x in rcd1 | −3.3x in rcd1 |
−2.3x in xlpra2 | ||||
RBP3 | n.s | n.s | n.s | n.s |
RCVRN | n.s | n.s | −2.6x in rcd1 | −2.4x in rcd1 |
−2.2x in xlpra2 | ||||
−2.0x in erd (11.9–14.1 w) | ||||
PR development/structure | Â | Â | Â | |
CRB1 | n.s | n.s | n.s | n.s |
NRL | n.s | −2.3x in rcd1 | −2.0x in rcd1 | −3.0x in rcd1 |
−3.2x in erd (6.4 w) | −2.0x in xlpra2 | |||
−3.7x in erd (8.3-9.9 w) | −5.8x in erd (11.9–14.1 w) | |||
NR2E3 | n.s | −2.0x in rcd1 | −2.8x in erd (6.4 w) | n.s |
RDS | n.s | −2.5x in rcd1 | −2.0x in rcd1 | −3.0x in rcd1 |